Current Report Filing (8-k)
January 10 2022 - 7:40AM
Edgar (US Regulatory)
0001034842
false
0001034842
2022-01-10
2022-01-10
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 10, 2022
RIGEL PHARMACEUTICALS, INC.
(Exact name of registrant as specified in
its charter)
Delaware
(State or other jurisdiction of incorporation)
0-29889
|
|
94-3248524
|
(Commission File No.)
|
|
(IRS Employer Identification No.)
|
|
|
|
1180 Veterans Boulevard
|
|
|
South San Francisco, CA
|
|
94080
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code: (650) 624-1100
Not Applicable
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
Title of Each Class
|
|
Trading
Symbol(s)
|
|
Name of Each Exchange on Which
Registered
|
Common Stock, par value $0.001 per share
|
|
RIGL
|
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
|
Item 2.02.
|
Results of Operations and Financial Condition.
|
In connection with the press release described
in Item 8.01 below, on January 10, 2022, Rigel Pharmaceuticals, Inc. (“Rigel”) provided, on a preliminary and unaudited
basis, certain estimated financial results for its fourth quarter and fiscal year ended December 31, 2021. The preliminary estimates are
based on currently available information and do not present all necessary information for a complete understanding of Rigel’s financial
condition as of December 31, 2021 or Rigel’s results of operations for the fourth quarter or year ended December 31, 2021.
On January 10, 2022, Rigel issued a press release
titled “Rigel Pharmaceuticals Provides Business Update.” A copy of the press release is attached hereto as Exhibit 99.1 and
incorporated herein by reference.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: January 10, 2022
|
RIGEL PHARMACEUTICALS, INC.
|
|
|
By:
|
/s/ Dolly A. Vance
|
|
Dolly A. Vance
|
|
Executive Vice President, General Counsel and Corporate Secretary
|
Rigel Pharmaceuticals (NASDAQ:RIGL)
Historical Stock Chart
From Apr 2024 to May 2024
Rigel Pharmaceuticals (NASDAQ:RIGL)
Historical Stock Chart
From May 2023 to May 2024